



FOR IMMEDIATE RELEASE

Cancer Advances to attend ASCO Gastrointestinal Cancers Symposium

Durham, NC, January 15, 2014 — Expert Dr. Jill P. Smith, M.D. of [Cancer Advances, Inc.](#) and Cato Research will attend ASCO's Gastrointestinal Cancers Symposium at Moscone West Building, San Francisco, California, United States of America this week. The Gastrointestinal Cancers Symposium is a multidisciplinary event which specializes in oncology of the pancreas, small bowel, and hepatobiliary tract; colon and rectum; and esophagus and stomach. Attendees will gather to network and exchange the latest research and science in these related cancers.

Jill P. Smith, M.D., Director of Clinical Gastroenterology and Oncology for Cancer Advances and [Cato Research](#), is a clinician scientist who is Board certified in Gastroenterology. She is a leading researcher in the field of Pancreatology and former President of the American Pancreas Association. She is the recipient of the European Basic Science research award for pancreas research. Dr. Smith served as the Director of Clinical and Translational Research in NIDDK at the National Institutes of Health until January 2014. As an independent researcher she has expertise in bench to bedside translational research, and FDA regulation. In October 2013 she served as the Moderator of the FDA GREAT-2 conference on conducting clinical trials in gastrointestinal disorders. Currently she is Full Professor at Georgetown University in Washington DC in the Department of Medicine, Division of Gastroenterology & Hepatology.

About Cancer Advances

Cancer Advances is a biotechnology company focused on impacting human health and suppressing the progression of gastrointestinal and other cancers by enhancing the adaptive immune system. The company is supported by the breadth and depth of expertise at CATO Research Ltd. and CATO BioVentures. Senior Management at Cancer Advances combines decades of experience in oncology and biological drug development. Cancer Advances has developed an intellectual property strategy that currently holds over 100 U.S. and worldwide patents and patent applications related to PAS. This broad intellectual property portfolio includes composition and use-protection for PAS.

Cancer
Advances is
DEDICATED
to enhancing
the immune system
and augmenting
human quality of life by
targeting the progression
of gastrointestinal cancers.

Cancer Advances
P | 919-361-2162
E | info@canceradvancesinc.com
www.canceradvancesinc.com

About CATO Research

Founded in 1988 by Dr. Allen Cato and Lynda Sutton and headquartered near Research Triangle Park, North Carolina, Cato Research is a full-service global contract research and development organization providing strategic and tactical support for clients in the pharmaceutical, biotechnology, and medical device industries. Services range from design and management of preclinical and clinical studies to submission of regulatory documents required for marketing approval. With a staff of approximately 300 and offices located in the United States, Europe, Canada, Israel, India, and South Africa, Cato Research consistently demonstrates an unsurpassed level of responsiveness, flexibility, attention to detail, and passion for bringing their sponsors' products to market with speed and cost-effectiveness. For more information about Cato Research, visit www.Cato.com.

About CATO BioVentures

[Cato BioVentures](http://www.CatoBioVentures.com) is the venture capital affiliate of Cato Research. For over 20 years, Cato BioVentures and Cato Research have partnered with entrepreneurs, academic institutions, and a broad base of biotechnology and pharmaceutical companies to advance a robust portfolio of successful product development programs. Through strategic CRO service agreements with Cato Research, Cato BioVentures has invested its CRO Service Capital® in innovative therapeutics, medical devices, and stem cell technologies that improve the pharmaceutical industry's research and development productivity. When strategic outsourcing for development, regulatory, and clinical support is a core component of a company's business plan, then Cato BioVenture's investment model can make a positive difference in the company's overall success. For more information about Cato BioVentures, call 919-361-2286 or visit www.CatoBioVentures.com.

Forward Looking Statements

This release contains certain forward-looking information based upon Cancer Advances' current plans, beliefs, expectations and projections. Cancer Advances is a privately-held company; any investment decision regarding Cancer Advances should rely only on the investor's own investigation into Cancer Advances, subject to the terms of the documents



governing that investment. In particular, no future results of any clinical trials or regulatory approval are guaranteed.

Please visit our product page for more information on what is in development:

<http://www.canceradvancesinc.com/product.html>

Contact: Lynda Sutton
President Cancer Advances, Inc.
Phone: 919-361-2162
Email: info@canceradvancesinc.com
www.canceradvancesinc.com

Cancer
Advances is
DEDICATED
to enhancing
the immune system
and augmenting
human quality of life by
targeting the progression
of gastrointestinal cancers.

Cancer Advances
P | 919-361-2162
E | info@canceradvancesinc.com
www.canceradvancesinc.com